Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma

International Journal of Gastrointestinal Cancer

Volumn 36, Issue 1, 2005, Pages 47-53

  Abbaszadegan, Mohammad Reza ^a   Raziee, Hamid Reza ^b   Ghafarzadegan, Kamran ^b   Shakeri, Mohammad Taghi ^c   Afsharnezhad, Sima ^d   Ghavamnasiry, Mohammad Reza ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Blood; Esophageal cancer; Familial; Methylation; p16 gene

Indexed keywords

CYCLIN D; DNA; PROTEIN KINASE; PROTEIN P16;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CYTODIAGNOSIS; CANCER RISK; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; DNA DETERMINATION; EARLY DIAGNOSIS; EPIGENETICS; ESOPHAGOSCOPY; ESOPHAGUS CARCINOMA; FAMILIAL CANCER; FEMALE; HIGH RISK POPULATION; HUMAN; INDUCED MUTATION; MALE; MEDICAL ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; RISK FACTOR; SQUAMOUS CELL CARCINOMA; SYMPTOM; TISSUE SECTION;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRAN; MALE; MIDDLE AGED; PEDIGREE; PROMOTER REGIONS (GENETICS); RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 26644457414     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Schrump DS, Altorki NK, Forastiere AA, Minsky BD. Cancer of the esophagus, in: Cancer Principles and Practice of Oncology. 6th Ed., Vol. 1, DeVita VT, Hellman S, and Rosenberg SA, eds. LWW Publishers, New York, NY, 2001, p. 1051.
2. Anker P, Mulcahy H, Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int J Cancer 2003;103:149-152.
3. Jeannon JP, Wilson JA. Cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors and their role in head and neck cancer. Clin Otolaryngol 1998;23:420-424.
4. Herman JG, Baylin Stephen B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054.
5. Rountree MR, Bachman KE, Herman JGI, Baylin SB. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001;20:3156-3165.
6. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11,891-11,896.
7. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
8. Tokugawa T, Sugihara H, Tani T, Hattori T. Modes of silencing of p16 in development of esophageal squamous cell carcinoma. Cancer Res 2002;62:4938-4944.
9. Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997;89:2500-2506.
10. Shiseki M, Rusin M. Detection of aberrant p16 methylation in serum of liver cancer patients. Cancer Res 1999;59:71-73.
11. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-895.
12. Hibi K, Taguchi M, Nakayama H, et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001;7:3135-3138.
13. Kamangar F, Strickland PT, Pourshams A, et al. High exposure to polycyclic aromatic hydrocarbons may contribute to high risk of esophageal cancer in northeastern Iran. Anti-cancer Res 2005;25:425-428.